
Sign up to save your podcasts
Or


A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.
By Janus Henderson Investors4.7
1414 ratings
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.

516 Listeners

1,176 Listeners

2,167 Listeners

1,866 Listeners

195 Listeners

12 Listeners

285 Listeners

56,382 Listeners

178 Listeners

898 Listeners

1,553 Listeners

107 Listeners

208 Listeners

303 Listeners

6 Listeners

3 Listeners